Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human (FIH) Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of single ascending doses of ABBV-0805

Next Previous
X
Search
Trial Profile

A first-in-human (FIH) Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of single ascending doses of ABBV-0805

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exidavnemab (Primary) ; Exidavnemab (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 27 Aug 2024 Results published in a BioArctic AB media release
    • 27 Aug 2024 According to a BioArctic AB media release, announced today that the results from two single-ascending dose phase-1 studies (M19-034 and M19-465) with exidavnemab have been published in The Journal of Clinical Pharmacology.
    • 28 Oct 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top